Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots.
Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots.
复制标题
DOI：
10.1093/rap/rkaa081
复制
发表时间：
2021
影响因子：
3.1
通讯作者：
Chandra B
中科院分区：
文献类型：
--
作者：
Tung ML;Tan B;Cherian R;Chandra B
由于由严重急性呼吸系统综合征冠状病毒2型（SARS-CoV-2）引起的2019年冠状病毒病（COVID-19）大流行正在全球范围内迅速蔓延，它已成为死亡的主要原因，在过去10个月内导致超过100万人死亡。COVID-19的病理生理学仍不清楚，对患者的医疗管理构成巨大挑战。最近的研究报告称，COVID-19患者的血栓栓塞事件发生率异常高，尽管其机制仍然难以捉摸。几项研究报告了COVID-19患者中存在aPL。我们注意到COVID-19和APS之间的相似性，APS是一种自身免疫性血栓前疾病，通常与感染性病因相关。分子拟态和内皮功能障碍可以解释获得性APS血栓形成的机制。在这篇综述中，我们讨论了COVID-19和APS之间的临床病理学相似性，以及基于抗磷脂模型的COVID-19疾病治疗靶点的潜在作用。
As the coronavirus disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly worldwide, it has emerged as a leading cause of mortality, resulting in >1 million deaths over the past 10 months. The pathophysiology of COVID-19 remains unclear, posing a great challenge to the medical management of patients. Recent studies have reported an unusually high prevalence of thromboembolic events in COVID-19 patients, although the mechanism remains elusive. Several studies have reported the presence of aPLs in COVID-19 patients. We have noticed similarities between COVID-19 and APS, which is an autoimmune prothrombotic disease that is often associated with an infective aetiology. Molecular mimicry and endothelial dysfunction could plausibly explain the mechanism of thrombogenesis in acquired APS. In this review, we discuss the clinicopathological similarities between COVID-19 and APS, and the potential role of therapeutic targets based on the anti-phospholipid model for COVID-19 disease.